WO2016010844A4 - Methods and compositions for the treatment of stroke - Google Patents
Methods and compositions for the treatment of stroke Download PDFInfo
- Publication number
- WO2016010844A4 WO2016010844A4 PCT/US2015/039900 US2015039900W WO2016010844A4 WO 2016010844 A4 WO2016010844 A4 WO 2016010844A4 US 2015039900 W US2015039900 W US 2015039900W WO 2016010844 A4 WO2016010844 A4 WO 2016010844A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiotensin
- peptide
- administered
- stroke
- potassium channel
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 69
- 208000006011 Stroke Diseases 0.000 title claims 19
- 239000000203 mixture Substances 0.000 title 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims abstract 49
- 229940125422 potassium channel blocker Drugs 0.000 claims abstract 22
- 239000003450 potassium channel blocker Substances 0.000 claims abstract 22
- 210000004556 brain Anatomy 0.000 claims abstract 19
- 150000001413 amino acids Chemical class 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 10
- 238000007385 chemical modification Methods 0.000 claims 4
- 238000007911 parenteral administration Methods 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 3
- 208000032382 Ischaemic stroke Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 201000004810 Vascular dementia Diseases 0.000 claims 3
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 3
- 230000009529 traumatic brain injury Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- MREBEPTUUMTTIA-PCLIKHOPSA-N Azimilide Chemical compound C1CN(C)CCN1CCCCN1C(=O)N(\N=C\C=2OC(=CC=2)C=2C=CC(Cl)=CC=2)CC1=O MREBEPTUUMTTIA-PCLIKHOPSA-N 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- WPSYTTKBGAZSCX-UHFFFAOYSA-N Clofilium Chemical compound CCCCCCC[N+](CC)(CC)CCCCC1=CC=C(Cl)C=C1 WPSYTTKBGAZSCX-UHFFFAOYSA-N 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000019505 Deglutition disease Diseases 0.000 claims 2
- 206010013887 Dysarthria Diseases 0.000 claims 2
- SRUISGSHWFJION-UHFFFAOYSA-N E-4031 Chemical compound CC1=CC=CC(CCN2CCC(CC2)C(=O)C=2C=CC(NS(C)(=O)=O)=CC=2)=N1 SRUISGSHWFJION-UHFFFAOYSA-N 0.000 claims 2
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010027951 Mood swings Diseases 0.000 claims 2
- OEBPANQZQGQPHF-UHFFFAOYSA-N Nifekalant Chemical compound O=C1N(C)C(=O)N(C)C(NCCN(CCO)CCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 OEBPANQZQGQPHF-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 229960005260 amiodarone Drugs 0.000 claims 2
- 201000007201 aphasia Diseases 0.000 claims 2
- 229950001786 azimilide Drugs 0.000 claims 2
- 229960002624 bretylium tosilate Drugs 0.000 claims 2
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 229960002994 dofetilide Drugs 0.000 claims 2
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 claims 2
- 229960002084 dronedarone Drugs 0.000 claims 2
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 claims 2
- 229960004979 fampridine Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 229960004053 ibutilide Drugs 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000018769 loss of vision Diseases 0.000 claims 2
- 231100000864 loss of vision Toxicity 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 229950008576 nifekalant Drugs 0.000 claims 2
- 230000006320 pegylation Effects 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- KHYPYQZQJSBPIX-UHFFFAOYSA-N sematilide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(NS(C)(=O)=O)C=C1 KHYPYQZQJSBPIX-UHFFFAOYSA-N 0.000 claims 2
- 229950008118 sematilide Drugs 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims 2
- 229960002370 sotalol Drugs 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 229960002926 tedisamil Drugs 0.000 claims 2
- CTIRHWCPXYGDGF-HDICACEKSA-N tedisamil Chemical compound [H][C@]12CN(CC3CC3)C[C@]([H])(CN(CC3CC3)C1)C21CCCC1 CTIRHWCPXYGDGF-HDICACEKSA-N 0.000 claims 2
- 230000004393 visual impairment Effects 0.000 claims 2
- SITWEMZOJNKJCH-WDSKDSINSA-N Ala-Arg Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SITWEMZOJNKJCH-WDSKDSINSA-N 0.000 claims 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides, among other things, methods of treating brain conditions including the steps of administering to a subject suffering from or who previously suffered from a brain condition at least one angiotensin (1-7) peptide, and administering to the subject at least one potassium channel blocker. In some embodiments, the present invention provides methods of treating brain conditions including the step of administering to a subject suffering from or who previously suffered from a brain condition, and was administered an angiotensin(1-7) peptide, a potassium channel blocker. In some embodiments, the present invention provides methods of treating brain conditions including the step of administering to a subject suffering from or who previously suffered from a brain condition, and was administered a potassium channel blocker, an angiotensin(1-7) peptide.
Claims
1. A method of treating a brain condition comprising
administering to a subject suffering from or who previously suffered from a brain condition at least one angiotensin (1-7) peptide; and
administering to the subject at least one potassium channel blocker.
2. The method of claim 1, wherein the brain condition is selected from stroke, vascular dementia, and traumatic brain injury.
3. The method of claim 2, wherein the stroke is either ischemic stroke, hemorrhagic stroke, or a combination thereof.
4. The method of claim 3, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered within 24 hours of a stroke.
5. The method of claim 3, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 24 hours after a stroke.
6. The method of claim 3, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 1 week after a stroke.
7. The method of claim 3, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 4 weeks after a stroke.
8. The method of claim 1, wherein the potassium channel blocker is selected from:
dalfampridine, amiodarone, dronedarone, dofetilide, sotalol, ibutilide, azimilide, bretylium, clofilium, E-4031, nifekalant, tedisamil, sematilide, and combinations thereof.
9. The method of claim 8, wherein the potassium channel blocker is administered at a dose other than an FDA-approved dose.
10. The method of claim 1, wherein the angiotensin (1-7) peptide is administered via parenteral administration, rectal administration, oral administration, or a combination thereof.
11. The method of claim 10, wherein the parenteral administration is intravenous, subcutaneous, inhalation, intradermal, transdermal, and/or transmucosal administration.
12. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at least once per day.
13. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1-1,000 ug/kg/day.
14. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1-500 ug/kg/day.
15. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1 -60 ug/kg/day.
16. The method of claim 1, wherein the angiotensin (1-7) peptide comprises the naturally-
1 2 3 4 5 6 V occurring Angiotensin (1-7) amino acid sequence of Asp -Arg -Val -Tyr -He -His -Pro (SEQ ID NO: 1).
17. The method claim 1, wherein the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO: 1.
18. The method of claim 17, wherein the functional equivalent is a linear peptide.
19. The method of claim 18, wherein the linear peptide comprises a sequence that includes at least four amino acids from the seven amino acids that appear in the naturally-occurring
Angiotensin (1-7), wherein the at least four amino acids maintain their relative positions as they appear in the naturally-occurring Angiotensin (1-7).
20. The method of claim 18, wherein the linear peptide contains 4-25 amino acids.
21. The method of claim 18, wherein the linear peptide is a fragment of the naturally- occurring Angiotensin (1-7).
22. The method of any one of claims 18-21, wherein the linear peptide contains amino acid substitutions, deletions and/or insertions in the naturally-occurring Angiotensin (1-7).
23. The method of any one of claims 18-21, wherein the linear peptide has an amino acid sequence of
(SEQ ID NO: 2).
24. The method of any one of claims 18-21, wherein the linear peptide has an amino acid sequence of
(SEQ ID NO: 3).
25. The method of any one of claims 1- 21, wherein the angiotensin (1-7) peptide comprises one or more chemical modifications to increase protease resistance, serum stability and/or bioavailability.
26. The method of claim 25, wherein the one or more chemical modifications comprise pegylation.
27. The method of claim 1, wherein the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one sign, symptom and/or feature of a brain condition is reduced in intensity, severity, duration, or frequency or has delayed onset.
28. The method of claim 27, wherein the at least one sign, symptom and/or feature of a brain condition is selected from paralysis, memory loss, pain, seizure, dysphagia, aphasia, dysarthria, ataxia, depression, mood swings, and loss of vision.
29. A method of treating a brain condition comprising
administering to a subject suffering from or who previously suffered from a brain condition, and was administered an angiotensin (1-7) peptide, a potassium channel blocker.
30. The method of claim 29, wherein the brain condition is selected from stroke, vascular dementia, and traumatic brain injury.
31. The method of claim 30, wherein the stroke is either ischemic stroke, hemorrhagic stroke, or a combination thereof.
32. The method of claim 31, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered within 24 hours of a stroke.
33. The method of claim 31, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 24 hours after a stroke.
34. The method of claim 31, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 1 week after a stroke.
35. The method of claim 31, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 4 weeks after a stroke.
36. The method of any one of claims 29-35, wherein the potassium channel blocker is selected from: dalfampridine, amiodarone, dronedarone, dofetilide, sotalol, ibutilide, azimilide, bretylium, clofilium, E-4031, nifekalant, tedisamil, sematilide, and combinations thereof.
37. The method of any one of claims 29-35, wherein the potassium channel blocker is administered at a dose other than an FDA-approved dose.
38. A method of treating a brain condition comprising
administering to a subject suffering from or who previously suffered from a brain condition, and was administered a potassium channel blocker, an angiotensin (1-7) peptide.
39. The method of claim 38, wherein the brain condition is selected from stroke, vascular dementia, and traumatic brain injury.
40. The method of claim 39, wherein the stroke is either ischemic stroke, hemorrhagic stroke, or a combination thereof.
41. The method of claim 40, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered within 24 hours of a stroke.
42. The method of claim 40, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 24 hours after a stroke.
43. The method of claim 40, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 1 week after a stroke.
44. The method of claim 40, wherein at least one of the angiotensin (1-7) peptide and potassium channel blocker are administered at least 4 weeks after a stroke.
45. The method of any one of claims 38-44, wherein the angiotensin (1-7) peptide is administered via parenteral administration, rectal administration, oral administration, or a combination thereof.
46. The method of claim 45, wherein the parenteral administration is intravenous, subcutaneous, inhalation, intradermal, transdermal, and/or transmucosal administration.
47. The method of claim 38, wherein the angiotensin (1-7) peptide is administered at least once per day.
48. The method of claim 38, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1-1,000 ug/kg/day.
49. The method of claim 38, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 50-500 ug/kg/day.
50. The method of claim 38, wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1 -60 ug/kg/day.
51. The method of claim 38, wherein the angiotensin (1-7) peptide comprises the naturally-
1 2 3 4 5 6 V occurring Angiotensin (1-7) amino acid sequence of Asp -Arg -Val -Tyr -He -His -Pro (SEQ ID NO: 1).
52. The method of claim 38, wherein the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO: 1.
53. The method of claim 52, wherein the functional equivalent is a linear peptide.
54. The method of claim 53, wherein the linear peptide comprises a sequence that includes at least four amino acids from the seven amino acids that appear in the naturally-occurring
Angiotensin (1-7), wherein the at least four amino acids maintain their relative positions as they appear in the naturally-occurring Angiotensin (1-7).
55. The method of claim 53, wherein the linear peptide contains 4-25 amino acids.
56. The method of claim 53, wherein the linear peptide is a fragment of the naturally- occurring Angiotensin (1-7).
57. The method of claim 53, wherein the linear peptide contains amino acid substitutions, deletions and/or insertions in the naturally-occurring Angiotensin (1-7).
58. The method of claim 53, wherein the linear peptide has an amino acid sequence of Asp1-
Arg2 ■Val3-Ser4-Ile5-His6-Cys7 (SEQ ID NO: 2).
59. The method of claim 53, wherein the linear peptide has an amino acid sequence of Ala -
Arg2 ■Val3-Ser4-Ile5-His6-Cys7 (SEQ ID NO: 3).
60. The method of claim 38, wherein the angiotensin (1-7) peptide comprises one or more chemical modifications to increase protease resistance, serum stability and/or bioavailability.
61. The method of claim 60, wherein the one or more chemical modifications comprise pegylation.
62. The method of claim 38, wherein the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one sign, symptom and/or feature of a brain condition is reduced in intensity, severity, duration, or frequency or has delayed onset.
63. The method of claim 62, wherein the at least one sign, symptom and/or feature of a brain condition is selected from paralysis, memory loss, pain, seizure, dysphagia, aphasia, dysarthria, ataxia, depression, mood swings, and loss of vision.
64. The method of any one of claims 1, 29 and 38, wherein the at least one angiotensin (1-7) peptide is a non-peptidic angiotensin (1-7) receptor agonist.
65. The method of claim 64, wherein the non-peptidic angiotensin (1-7) receptor agonist is a compound with the following structure:
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024427P | 2014-07-14 | 2014-07-14 | |
| US62/024,427 | 2014-07-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2016010844A1 WO2016010844A1 (en) | 2016-01-21 |
| WO2016010844A4 true WO2016010844A4 (en) | 2016-03-24 |
Family
ID=55078929
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2015/039900 WO2016010844A1 (en) | 2014-07-14 | 2015-07-10 | Methods and compositions for the treatment of stroke |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016010844A1 (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005265098B2 (en) * | 2004-06-17 | 2012-02-23 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| BRPI1103387B1 (en) * | 2011-07-21 | 2022-04-19 | Universidade Federal De Minas Gerais | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ARTERIAL HYPERTENSION BASED ON THE CO-ADMINISTRATION OF ANTI-HYPERSTENSIVES AND ANGIOTENSIN (1-7) OR OTHER MAS RECEPTOR AGONIST |
| US8633158B1 (en) * | 2012-10-02 | 2014-01-21 | Tarix Pharmaceuticals Ltd. | Angiotensin in treating brain conditions |
| US9333233B2 (en) * | 2014-02-25 | 2016-05-10 | Tarix Pharmaceuticals Ltd. | Methods and compositions for the delayed treatment of stroke |
-
2015
- 2015-07-10 WO PCT/US2015/039900 patent/WO2016010844A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016010844A1 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008716A (en) | Camptothecin compound, preparation method therefor, and application thereof. | |
| EP3744340A3 (en) | Compositions and methods for treating cancer | |
| CO2018000375A2 (en) | Methods for the treatment of developmental disorders with gaboxadol | |
| ZA202202410B (en) | Rna particles comprising polysarcosine | |
| WO2012142320A8 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP2015524849A5 (en) | ||
| AU2018205186B2 (en) | Angiotensin in treating brain conditions | |
| Liu et al. | Polarization of M1 tumor associated macrophage promoted by the activation of TLR3 signal pathway | |
| EP4265254A3 (en) | Imidazo[4,5-b]pyridine compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| NZ702178A (en) | Lingo-2 antagonists for treatment of conditions involving motor neurons | |
| FI3261661T3 (en) | Menotropin for treating infertility | |
| JP2018506506A (en) | Neurodegenerative disorder | |
| MX2021011230A (en) | Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases. | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2018102670A3 (en) | Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down | |
| RU2014103246A (en) | COMPOUNDS AND PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE AND ISCHEMIC BRAIN DISEASES | |
| WO2016010844A4 (en) | Methods and compositions for the treatment of stroke | |
| MX2019005466A (en) | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia. | |
| WO2016081369A4 (en) | Alkaloid compounds for treating depression, substance addictions, and indications associated with chronic inflammation | |
| BR112022009898A2 (en) | COMPOSITIONS AND METHODS FOR DEREPRESSION OF RE1 SILENCER TRANSCRIPTION FACTOR TARGET GENES | |
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| CA3152488A1 (en) | Combination therapy using extracellular vesicles | |
| WO2022133098A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| RU2015119472A (en) | THERAPEUTIC FOR LATERAL AMYOTROPHIC SCLEROSIS | |
| KR102657418B1 (en) | Use of CGRP receptor antagonists in neuroprotection and neurological diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15822465 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15822465 Country of ref document: EP Kind code of ref document: A1 |